Archaea: Microbial Candidates in Next-generation Probiotics Development : Journal of Clinical Gastroenterology

Secondary Logo

Journal Logo

Advanced Search
PRESENTATION

Archaea

Microbial Candidates in Next-generation Probiotics Development

Brugère, Jean-François PhD*; Ben Hania, Wajdi PhD*,†; Arnal, Marie-Edith PhD*; Ribière, Céline PhD‡; Ballet, Nathalie PhD§; Vandeckerkove, Pascal PhD§; Ollivier, Bernard PhD†; O’Toole, Paul W. PhD‡

Author Information

*UMR 454 MEDIS, INRA-UCA, Université Clermont-Auvergne, Clermont-Ferrand

†Aix Marseille Université, CNRS, Université de Toulon, IRD, Mediterranean Institute of Oceanography (MIO), Marseille

§Lesaffre International, Lesaffre Group, Marcq-en-Barœul, France

‡School of Microbiology & APC Microbiome Institute, University College Cork, Cork, Ireland

P.W.O.T.’s laboratory is supported by Science Foundation Ireland through a Centre award to the APC Microbiome Institute (SFI/12/RC/2273). Work in J.-F.B. and P.W.O.T.’s laboratories was funded in part by a nonrestrictive award from Lesaffre International for research development on some aspects of Methanomassiliicoccales biology. The remaining authors declare that they have nothing to disclose.

Address correspondence to: Jean-François Brugère, PhD, UMR 454 MEDIS, INRA-UCA, Université Clermont-Auvergne, 5e CBRV, 28 Place Henri Dunant, F-63000, Clermont-Ferrand, France (e-mail: [email protected]).

Journal of Clinical Gastroenterology 52():p S71-S73, November/December 2018. | DOI: 10.1097/MCG.0000000000001043

Abstract

Pharmabiotics and probiotics in current use or under development belong to 2 of 3 domains of life, Eukarya (eg, yeasts) and Bacteria (eg, lactobacilli). Archaea constitute a third domain of life, and are currently not used as probiotics, despite several interesting features. This includes the absence of known pathogens in humans, animals, or plants and the existence of some archaea closely associated to humans in various microbiomes. We promote the concept that some specific archaea that naturally thrive in the human gut are potential next-generation probiotics that can be rationally selected on the basis of their metabolic phenotype not being encountered in other human gut microbes, neither Bacteria nor Eukarya. The example of the possible bioremediation of the proatherogenic compound trimethylamine into methane by archaeal microbes is described.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.

Full Text Access for Subscribers:

Not a Subscriber?

Buy
Request Permissions

You can read the full text of this article if you:

Access through Ovid